Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C1 | Q04828 | 7/20 | 0.59 |
| ▸ | AKR1C3 | P42330 | 11/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | AKR1C2 | P52895 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3290496 | 1.00 | AKR1C1 (0.59) | AKR1C1AKR1C3ALDH1A1HTTAKR1C2 | |
| SCHEMBL20184151 | 0.78 | AKR1C1 (0.75) | AKR1C1AKR1C3ALDH1A1HTTAKR1C2 | |
| SCHEMBL7814861 | 0.78 | AKR1C1 (0.75) | AKR1C1AKR1C3ALDH1A1HTTAKR1C2 | |
| SCHEMBL2524591 | 0.78 | HTT (0.58) | AKR1C1AKR1C3ALDH1A1HTTAKR1C2 | |
| SCHEMBL1225004 | 0.78 | AKR1C1 (0.72) | AKR1C1AKR1C3ALDH1A1HTTAKR1C2 | |
| SCHEMBL14591173 | 0.76 | AKR1C1 (0.78) | AKR1C1AKR1C3ALDH1A1HTTAKR1C2 | |
| SCHEMBL1981785 | 0.76 | AKR1C1 (0.78) | AKR1C1AKR1C3ALDH1A1HTTAKR1C2 | |
| SCHEMBL10805993 | 0.76 | MAPT (0.50) | AKR1C1AKR1C3ALDH1A1HTTMEN1 | |
| SCHEMBL39275 | 0.75 | AKR1C1 (1.00) | AKR1C1AKR1C3ALDH1A1HTTAKR1C2 | |
| SCHEMBL181529 | 0.75 | AKR1C1 (1.00) | AKR1C1AKR1C3ALDH1A1HTTAKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1896399-B1 | BIPHENYL AND NAPHTHYL-PHENYL HYDROXAMIC ACID DERIVATIVES | SIGMA TAU IND FARMACEUTI (IT) | 2010-11-17 | — | — | EP | disclosed |
| US-7728039-B2 | Biphenyl and Naphthyl-Phenyl Hydroxamic Acid Derivatives | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2010-06-01 | — | — | US | disclosed |
| US-20080319082-A1 | Biphenyl and Naphthyl-Phenyl Hydroxamic Acid Derivatives | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319082-A1 | Biphenyl and Naphthyl-Phenyl Hydroxamic Acid Derivatives | VHL, ARNT, AHR | AKR1C1 2535/4885AKR1C3 2257/4885ALDH1A1 1055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.